Pfizer (PFE) acquires exclusive rights to commercialise obesity therapy in China and is to pay Hangzhou Sciwind Biosciences up to USD 495mln
Importance
Level 1
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#PFIZER INC#PFE.US#FOREX#EQUITIES#METALS#ASIAN SESSION#EXCLUSIVE#PHARMACEUTICALS#METALS & MINING#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#DXY#US EQUITIES